IL22 and psoriasis: Remarkably, treatment of 17A-Lytaca markedly decreased the mRNA expression of IL-17A and its downstream psoriasis-related inflammatory cytokines in the skin lesion, including IL-6, CCL-20, and IL-22, compared with the positive group.